Incretin Atlas › Trials › SUMMIT
SUMMIT
Tirzepatide · HFpEF + obesity
Design
- Molecule(s)
- Tirzepatide
- Population
- HFpEF + obesity
- Official title
- A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT Trial
- Sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Registry status
- completed · 2021-04 → 2024-07
- Participants
- 731
- Duration
- 104 weeks
- Registry
- NCT04847557
Cardiovascular and kidney outcomes
SUMMIT tirzepatide 5–15 mg vs placebo · HFpEF + obesity · n = 731 · 2024 verified
| Endpoint | HR | 95 % CI | Events, drug vs control | Status |
|---|---|---|---|---|
| Cardiovascular death Adjudicated death from cardiovascular causes (excludes 2 tirzepatide deaths of undetermined cause, which are counted as CV deaths in the composite) | 1.58 | 0.52–4.83 | 8 vs 5 | verified |
| All-cause death Death from any cause | 1.25 | 0.63–2.45 | 19 vs 15 | verified |
| Hospitalisation for heart failure Adjudicated worsening heart-failure event resulting in hospitalization (first event) | 0.44 | 0.22–0.87 | 12 vs 26 | verified |
| CV death or worsening HF primary Adjudicated CV death (including undetermined cause) or worsening heart-failure event (hospitalization, IV therapy in urgent care, or intensified oral diuretics) | 0.62 | 0.41–0.95 | 36 vs 56 | verified |
Verbatim quotes (4)
- Cardiovascular death · Abstract; Table 2
adjudicated death from cardiovascular causes occurred in 8 patients (2.2%) and 5 patients (1.4%), respectively (hazard ratio, 1.58; 95% CI, 0.52 to 4.83)
- All-cause death · Results, Primary End Points; Table 2
Death from any cause occurred in 19 patients in tirzepatide group and in 15 patients in the placebo group (hazard ratio, 1.25; 95% CI, 0.63 to 2.45)
- Hospitalisation for heart failure · Table 2
Adjudicated worsening heart-failure event resulting in hospitalization — no. (%) 12 (3.3) 1.8 26 (7.1) 3.9 0.44 (0.22 to 0.87)
- CV death or worsening HF · Results, Primary End Points; Table 2; Figure 1
occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (...hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P = 0.026)
Outcomes in the indication
SUMMIT Tirzepatide · HFpEF + obesity · 104 weeks · n = 731 seed
CV death or worsening HF HR 0.62; KCCQ-CSS +6.9 points
| Measure | Drug | Control | Difference (95 % CI) | Status |
|---|---|---|---|---|
| Cardiovascular death or worsening heart-failure event (time to first event) week 104 | +9.9 | +15.3 | +0.6 (+0.4 to +0.9) hazard ratio | verified |
| KCCQ clinical summary score, change from baseline week 52 | +19.5 | +12.7 | +6.9 (+3.3 to +10.6) points (0-100) | verified |
Verbatim quotes (2)
- Cardiovascular death or worsening heart-failure event (time to first event)
Adjudicated death from cardiovascular causes or a worsening heart-failure event occurred in 36 patients (9.9%) in the tirzepatide group and in 56 patients (15.3%) in the placebo group (hazard ratio, 0.62; 95% confidence interval [CI], 0.41 to 0.95; P = 0.026)
- KCCQ clinical summary score, change from baseline
the mean (±SD) change in the KCCQ-CSS was 19.5±1.2 in the tirzepatide group as compared with 12.7±1.3 in the placebo group (between-group difference, 6.9; 95% CI, 3.3 to 10.6; P<0.001)
Primary sources
- Packer M, Zile MR, Kramer CM, Baum SJ, Litwin SE, Menon V, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. N Engl J Med. 2025;392(5):427-437. PMID: 39555826.
- Eli Lilly and Company. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study Comparing the Efficacy and Safety of Tirzepatide Versus Placebo in Patients With Heart Failure With Preserved Ejection Fraction and Obesity (SUMMIT). ClinicalTrials.gov identifier NCT04847557. Bethesda (MD): National Library of Medicine. Available from: https://clinicaltrials.gov/study/NCT04847557
How to cite this page
Medical Adviser's Group. Incretin Atlas: SUMMIT. Data cut 12 November 2026. https://docs.mdwrt.app/infographics/incretin-atlas/trials/summit/ Data: doi:10.5281/zenodo.23473913. Accessed 16 November 2026.
Cite the primary publication for any single result; every value above links to it.